> Catalent's fourth-quarter revenue spiked 13% to $478 million, thanks largely to its February acquisition of Aptuit. Report
> CROs in Central Europe have been fighting for market share of late, and a new report says the clinical trial market there will grow by about 7% per year through 2014. More
> China's WuXi PharmaTech has signed a deal to manufacture the HIV drug ibalizumab for TaiMed Biologics. News
> The Regulatory Affairs Professionals Society says CROs in emerging markets can benefit from taking the organization's test, bringing them up to speed on regulatory requirements around the world. Article
> CMC Biologics has appointed a new general manager for its Denmark CMO facility, tapping Patricio Massera to head the plant. Story
> The progress of personalized medicine suggest that whether or not a treatment is effective is based on a complex network of varying genes, flying in the face of the FDA's methods of isolating variables in clinical trials. What does that mean for the future of drug research? Item